Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
314.6 USD | +2.79% | -5.28% | -12.93% |
May. 30 | JPMorgan Adjusts Price Target on Molina Healthcare to $420 From $435 | MT |
May. 30 | Baird Initiates Molina Healthcare With Outperform Rating, $405 Price Target | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.38 for the 2024 fiscal year.
- The company has a low valuation given the cash flows generated by its activity.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company does not generate enough profits, which is an alarming weak point.
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.93% | 18.43B | B- | ||
+14.19% | 125B | A- | ||
+15.08% | 97.9B | B- | ||
-21.78% | 43.15B | A- | ||
-3.53% | 38.2B | B- | ||
-27.51% | 2.57B | C+ | ||
-8.59% | 1.51B | B- | ||
+15.53% | 546M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MOH Stock
- Ratings Molina Healthcare, Inc.